About OncoMark
OncoMark is a company based in Dublin (Ireland) founded in 2011 was acquired by Cepheid in December 2021. OncoMark has raised $6.72 million across 5 funding rounds from investors including Cepheid, European Commission and Enterprise Ireland. OncoMark operates in a competitive market with competitors including DermTech, NeuMoDx, Biomeme, Molbio Diagnostics and OncoStem, among others.
- Headquarter Dublin, Ireland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of OncoMark
OncoMark has successfully raised a total of $6.72M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $4.5 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OncoMark
OncoMark has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Cepheid, European Commission and Enterprise Ireland.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
A platform connecting angel investors to startups in Ireland.
|
Locked | Locked | Locked | |
|
VC firm investing in the UK and the US
|
Locked | Locked | Locked |
Investor details for OncoMark
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OncoMark
Investment portfolio details for OncoMark
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OncoMark
Detailed financials for OncoMark
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oncomark Comparisons
Peer comparison for OncoMark
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OncoMark
OncoMark operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DermTech, NeuMoDx, Biomeme, Molbio Diagnostics and OncoStem, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Adhesive patch biopsies for skin cancer detection are provided.
|
|
| Locked | Locked | Locked |
Developer of a platform for low cost molecular testing
|
|
| Locked | Locked | Locked |
Smartphone-based DNA detection platform is developed for diagnostics.
|
|
| Locked | Locked | Locked |
Point-of-care molecular platforms for infectious disease detection are developed.
|
|
| Locked | Locked | Locked |
Prognostic tests for cancer detection and recurrence risk are developed.
|
|
| Locked | Locked | Locked |
Point-of-care molecular diagnostics are enabled by Ultrafast Photonic PCR technology.
|
Detailed competitors of OncoMark
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncomark
Complete news archive for OncoMark
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OncoMark
OncoMark was founded in 2011 and raised its 1st funding round 3 years after it was founded.
OncoMark is headquartered in Dublin, Ireland.
OncoMark is a funded company, having raised a total of $6.72M across 5 funding rounds to date.
OncoMark was founded in 2011 and is based in Dublin, Ireland. Tissue-based diagnostics for cancer are developed by the company within the biotechnology sector. The flagship OncoMasTR qPCR assay is utilized to assess recurrence risk in early-stage breast cancer patients through gene analysis. Additional products for melanoma, colorectal cancer, and prostate cancer are under development. Operations focus on prognostic tools for oncology applications.
OncoMark's top competitors include DermTech, Molbio Diagnostics and NeuMoDx.
OncoMark has 7 investors. Key investors include Cepheid, European Commission, Enterprise Ireland, European Union, and Irrus Investments.